American International Group, Inc. Aadi Bioscience, Inc. Transaction History

American International Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.59 - $2.44 $109 - $168	-69 Reduced 0.86%	7,993 $18,000
Q4 2023 Feb 13, 2024	SELL	$1.97 - $5.41 $63 - $173	-32 Reduced 0.4%	8,062 $16,000
Q3 2023 Nov 13, 2023	BUY	$4.84 - $7.13 $1,393 - $2,053	288 Added 3.69%	8,094 $39,000
Q2 2023 Aug 04, 2023	BUY	$6.84 - $8.56 $5,588 - $6,993	817 Added 11.69%	7,806 $53,000
Q1 2023 May 12, 2023	BUY	$6.85 - $13.0 $959 - $1,820	140 Added 2.04%	6,989 $50,000
Q4 2022 Feb 10, 2023	SELL	$11.99 - $14.5 $299 - $362	-25 Reduced 0.36%	6,849 $87,000
Q3 2022 Nov 14, 2022	BUY	$12.03 - $14.22 $1,166 - $1,379	97 Added 1.43%	6,874 $97,000
Q2 2022 Aug 12, 2022	BUY	$11.57 - $17.92 $78,409 - $121,443	6,777 New	6,777 $83,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $46.7M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.